Cancer Research: After 25 Years, A Big Payoff
Doctors are usually careful not to oversell experimental cancer treatments, but investigators studying a new breast cancer drug are having trouble containing their excitement. On May 17, researchers reported that Genentech Inc.'s Herceptin dramatically slowed breast cancer and added months--in some cases, years--to the lives of patients suffering from the most aggressive form. "This is the biggest difference I've ever seen" in a study of advanced cancer patients, says Dr. Larry Norton, an oncologist at New York's Memorial Sloan-Kettering Cancer Center.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Tesla Unveils ‘World’s Fastest Production Car’ and Electric Big Rig
- Goldman Sachs Sees Four 2018 Fed Rate Hikes as U.S. Growth Gains
- Norway Idea to Exit Oil Stocks Is ‘Shot Heard Around the World’
- Honda Recalls 800,000 Odyssey Minivans Linked to Injuries
- Why Are Critics Calling the $450 Million Painting Fake?